Holen Sie sich die Stockscreener-App
8.07
2.15%
0.17
Schlusskurs vom Vortag:
$7.90
Offen:
$7.95
24-Stunden-Volumen:
1.04M
Relative Volume:
0.95
Marktkapitalisierung:
$399.83M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.5342
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+2.41%
1M Leistung:
+4.40%
6M Leistung:
-43.37%
1J Leistung:
-34.50%
1-Tages-Spanne:
$7.68
$8.63
1-Wochen-Bereich:
$7.23
$8.63
52-Wochen-Spanne:
$6.56
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie RGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.07 | 399.83M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Vanguard Group Inc Reduces Stake in Regenxbio Inc - GuruFocus.com
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 - Longview News-Journal
Objective long/short (RGNX) Report - Stock Traders Daily
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? - MSN
REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
Analysts Offer Predictions for REGENXBIO FY2029 Earnings - MarketBeat
REGENXBIO’s (RGNX) Outperform Rating Reaffirmed at Royal Bank of Canada - Defense World
REGENXBIO's (RGNX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
$810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership - geneonline
Assenagon Asset Management S.A. Purchases 296,700 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN
(RGNX) Technical Data - Stock Traders Daily
Nippon Shinyaku, REGENXBIO partner for MPS treatments in U.S. and Asia -January 17, 2025 at 08:01 am EST - Marketscreener.com
REGENXBIO Enters Strategic Partnership with Nippon Shinyaku for Development of Gene Therapies - Defense World
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku - News & Insights
REGENXBIO: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again (NASDAQ:RGNX) - Seeking Alpha
Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma
Regenxbio maintained at Buy rating by H.C. Wainwright post partnership announcement - Investing.com India
Regenxbio maintained at Buy by H.C. Wainwright post partnership announcement - Investing.com
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright - MarketBeat
Regenxbio inks MPS drugs collab with Nippon Shinyaku - The Pharma Letter
Harbor Capital Advisors Inc. Has $198,000 Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
GAMMA Investing LLC Acquires 2,510 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
AbbVie, REGENXBIO advance gene therapy for eye diseases By Investing.com - Investing.com Australia
Rockville’s RegenxBio Enters $810 Million Partnership with Japanese Firm to Launch New Treatments - The MoCoShow
Rockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon Shinyaku - The Business Journals
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive
Regenxbio stock hits 52-week low at $7.13 amid market challenges - Investing.com Australia
RegenXBio Partners with Nippon Shinyaku on Gene Therapies - TipRanks
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku By Investing.com - Investing.com Australia
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku - Investing.com
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - Longview News-Journal
Barclays PLC Raises Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
AbbVie, REGENXBIO advance gene therapy for eye diseases - Investing.com India
AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program - StreetInsider.com
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program - Longview News-Journal
Regenxbio stock hits 52-week low at $7.13 amid market challenges By Investing.com - Investing.com South Africa
Regenxbio stock jumps 13% on positive data for DMD drug - MSN
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus.com
Jane Street Group LLC Sells 35,994 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio price target lowered to $22 from $25 at BofA - Yahoo Finance
JPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
JPMorgan Chase & Co. Cuts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regenxbio Inc-Aktie (RGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):